Pharmacoeconomic analysis of physiotens in patientswith arterial hypertension, overweight and type 2 diabetes mellitusin framework of Russian Public Health System
https://doi.org/10.14341/2071-8713-5245
Abstract
The present article represent a pharmacoeconomic comparison of standard antihypertensive therapy and the same therapy plus moxonidine (Physiotens) in patients with arterial hypertension, overweight and diabetes mellitus type 2. The budget impact analysis was conducted on outpatient and inpatient care basis. Moxonidine showеd convincing advantages compared to standard antihypertensive therapy such as the stroke risk reduction by 6 percent, reduction of doses antihypertensive and hypoglycemic drugs, which resulted in substantial decrease of direct medical costs.
References
1. Беленков Ю.Н., Чазова И.Е., Мычка В.Б. Многоцентровое рандомизированное открытое исследование по изучению эффективности изменения образа жизни и терапии ингибитором АПФ (квинаприлом) у больных ожирением и артериальной гипертонией (ЭКО)/Артериальные гипертензии 2003;9(6):196-199.
2. Чазова И.Е., Мычка В.Б. Открытая, многоцентровая, рандомизированная, научно-практическая программа МИНОТАВР: промежуточный анализ результатов/Кардиоваскулярная терапия и профилактика 2006;2:81-88.
3. Чазова И.Е., Мычка В.Б., Беленков Ю.Н. Первые результаты Российской программы "Апрель" (Эффективность применения акарбозы у пациентов с нарушенной толерантностью к глюкозе и артериальной гипертонией)/ Ожирение и метаболизм, 2005; №1(3), стр. 13-21.
4. Приказ Министерства здравоохранения и социального развития Российской Федерации от 01.08.2007 №513 «Об утверждении стандарта медицинской помощи больным инсультом)».
5. Haenni A., Lithel H. Moxonodine improves insulin resistance in obese, insulinresistant patients with moxonidine. J. Hypertens. 1999; 17 (Suppl): S24-S35.
6. Krentz A.J., Evans A.J. (1998) Selective imidazoline receptor agonists for metabolic syndrome. Lancet, 351()9097:152-153.
7. Rupp H., Dhalla K.S., Dimlla N.S.: Mechanism of cardiac cell damage due to catecholamines Significance of drugs regulating central sympathetic outflowJ. Cardiovascular. Pharmacol. 24(Suppl 1) S16-S24 1994.
8. Ernsberger P. Pharmacology of rnoxonidine An 11 -imidazoline receptor agonist. J. Cardiovascular. Pharmacol. 35(Suppl 4) S27-S41 2000.
9. Dahlof В., Sever P.S., Poulter N.R., et al., for the ASCOT Investigators Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required vs atenolol adding bendroflumethiazide as required, in the ASCOT-BPLA: a multicenter randomised controlled trial. Lancet 2005;366:895-906.
10. Littlewood K.J., Greiner W., Baum D., Zoellner Y. Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure BMC Nephrol. 2007; 8:9.
11. Abellan J., Leal M., Hernandez-Menarguez F. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. Kidney International, Vol. 67 (Suppl 93) S20-S24 2005.
12. Zimmet P., Shaw J., Alberti G. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabetic medicine 2003;20(9):693-702.
13. Mamedov M., Suslonova N., Lisenkova I., et al. Metabolic syndrome prevalence in Russia: Prelimonary results of a cross-sectional population study. Diabetic and Vascular Disease research 2007;4(1):46-47.
14. DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet. 1999;354:617-621.
15. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249-1258. (6-7).
16. Hans T.S., Feskens E.J., Lean M.E. Association of body composition with type 2 diabetes mellitus. Diab. Med. 15:129-135.1998.
17. Folsom A.R., Rasmussen M.L., Chambless L.E.: Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. Diabetes Care 22:1077-1083,1999.
18. Sanjuliani A.F., Genelhu deAbreu V., Ueleres BragaJ., et al. Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma aldosterone, leptin, and metabolic profile in obese hypertensive patients. J. Clin. Basic. Cardiol. 2004; 7:19-25.
19. Sharma A.M., Wagner Т., Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J. Hum. Hypertens. 2004 Sep; 18 (9): 669-75.
20. Chazova I.E., Almazov V.A, Shlyakhto E.V. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Diabetes, Obesity and Metabolism 2006; 8: 456-65
21. Ziegler D., Haxhiu M.A, Kaan E.C. Pharmacology of moxonidine, an 11-imidazoline receptor antagonist J Cardiovascular Prarmacol 27(Suppl3) S26-S37.1996.
Review
For citations:
Pharmacoeconomic analysis of physiotens in patientswith arterial hypertension, overweight and type 2 diabetes mellitusin framework of Russian Public Health System. Obesity and metabolism. 2009;6(3):48-52. (In Russ.) https://doi.org/10.14341/2071-8713-5245
Views:
400
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
